Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer

Pancreas

Volumn 38, Issue 7, 2009, Pages 782-790

  Galloway, Nicholas R ^a   Aspe, Jonathan R ^a   Sellers, Chelsey ^a   Wall, Nathan R ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gemcitabine; Inhibitor of apoptosis; Polyploidy; Proton irradiation; Survivin; XIAP

Indexed keywords

DNA; GEMCITABINE; INHIBITOR OF APOPTOSIS PROTEIN; SMALL INTERFERING RNA; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA CONTENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON RADIATION; RADIOSENSITIVITY; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TIME FACTORS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 70349911828     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181a85999     Document Type: Article

References (35)

1. Kleeff J, Michalski C, Friess H, et al. Pancreatic cancer: from bench to 5-year survival. Pancreas. 2006;33(2):111-118. (Pubitemid 44174558)
2. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173-180.
3. Müller MW, Friess H, Köninger J, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195(2):221-228.
4. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer. 2007; 97(2):145-151.
5. Reni M, Cereda S, Galli L. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett. 2007;256(1):25-28. (Pubitemid 47334967)
6. Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs. 2007;67(16):2293-2310. (Pubitemid 350071043)
7. Olsen DR, Bruland OS, Frykholm G, et al. Proton therapy - a systematic review of clinical effectiveness. Radiother Oncol. 2007; 83(2):123-132. (Pubitemid 46776914)
8. Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005;62(2):494-500.
9. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953-964. (Pubitemid 350002861)
10. DeLaney TF. Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. Technol Cancer Res Treat. 2007;6(suppl 4): 61-66.
11. Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86(6):886-892. (Pubitemid 34271023)
12. Kami K, Doi R, Koizumi M, et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery. 2004;136(2):443-448. (Pubitemid 39037686)
13. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92(2):271-278. (Pubitemid 32664432)
14. Li F. Survivin study: what is the next wave? J Cell Physiol. 2003;197(1):8-29.
15. Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys. 2007;67(5):1519-1525.
16. Asanuma K, Kobayashi D, Furuya D, et al. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res. 2002; 93(9):1057-1062. (Pubitemid 35154273)
17. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108(7):981-990. (Pubitemid 32946072)
18. Pennati M, Binda M, Colella G, et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol. 2003;120(4):648-654. (Pubitemid 36344009)
19. Kami K, Doi R, Koizumi M, et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery. 2005;138(2):299-305. (Pubitemid 41253814)
20. Lee JU, Hosotani R, Wada M, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer. 1999;35(9):1374-1380. (Pubitemid 29397439)
21. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1999;1(8):461-466. (Pubitemid 129503664)
22. O'Connor DS, Wall NR, Porter AC, et al. A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002;2(1):43-54.
23. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 2007;27(1): 17-28. (Pubitemid 46991388)
24. Moertel CG, Childs DS Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865-867.
25. Park JK, Ryu JK, Lee JK, et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas. 2006;33(4):397-402. (Pubitemid 44690731)
26. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403- 2413.
27. Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2): 444-453. (Pubitemid 47380086)
28. Giagkousiklidis S, Vellanki SH, Debatin KM, et al. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene. 2007;26(49):7006-7016. (Pubitemid 350014607)
29. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther. 2007;6(3): 957-966. (Pubitemid 46554565)
30. Comai L. The advantages and disadvantages of being polyploid. Nat Rev Genet. 2005;6(11):836-846.
31. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol. 2004;5(1):45-54. (Pubitemid 38089840)
32. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev. 2007;17(2):157-162.
33. Mufti AR, Burstein E, Duckett CS. XIAP: cell death regulation meets copper homeostasis. Arch Biochem Biophys. 2007; 463(2):168-174. (Pubitemid 47030333)
34. Lee KB, Kim KR, Huh TL, et al. Proton induces apoptosis of hypoxic tumor cells by the p53-dependent and p38/JNK MAPK signaling pathways. Int J Oncol. 2008;33(6):1247-1256.
35. Thayaparasingham B, Kunz A, Peters N, et al. Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of XIAP. Oncogene. 2009;28(3):345-362.